

Corp. Reg. No. 556966-4955  
April 17, 2023



## Elicera Therapeutics publishes the annual report for 2022

**Gothenburg, April 17, 2023 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, publishes the annual report for 2022.**

Elicera Therapeutics annual report is now available at the webpage <https://www.elicera.com>.

The Annual General Meeting will be held on May 16<sup>th</sup> at 3:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).

**For further information please contact:**

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51

[jamal.elmosleh@elicera.com](mailto:jamal.elmosleh@elicera.com)

**Certified Advisor**

Erik Penser Bank

*The information was submitted for publication distributed through the contact person above at 15:09 CET on April 17, 2023.*

**About Elicera Therapeutics AB**

*Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next-generation therapies based on oncolytic viruses and CAR T-cells, armed with the company’s proprietary and commercially available platform, iTANK. The work is based on high-profile long-standing research conducted by Professor Magnus Essand’s research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. The iTANK-platform is used to arm the company’s own CAR T-cells, in addition to the oncolytic virus ELC-201, but can also be universally applied to other CAR/TCR T-cell therapies under development. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit [www.elicera.com](http://www.elicera.com)*